Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Study of MCS110 Combined With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

Next Previous
Trial Profile

A Randomized Phase II Study of MCS110 Combined With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lacnotuzumab (Primary) ; Carboplatin; Gemcitabine
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals

Most Recent Events

  • 06 Oct 2021 a protocol amendment after the enrollment halt where survival follow-up was removed, biomarker sample collections were no longer required and the frequency of post Cycle 8 assessments was reduced from every 9 weeks to a minimum of every 12 weeks until disease progression, and at the end-of-treatment visit, as per results published in the Clinical Cancer Research
  • 06 Oct 2021 Primary endpoint (Progression Free Survival (PFS) as Per RECIST v1.1 (by Local Investigator Assessment)) has not been met as per results published in the Clinical Cancer Research
  • 06 Oct 2021 Results published in the Clinical Cancer Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top